Volume 77, Issue 5 (August 2019)
Tehran Univ Med J 2019, 77(5): 288-293 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Salehi A, Abtahi M, Abtahi S, Razmjou H, Tohidi M, Akbari M et al . Baseline subfoveal choroidal thickness as an indicator for bevacizumab outcomes in central retinal vein occlusion. Tehran Univ Med J 2019; 77 (5) :288-293
URL: http://tumj.tums.ac.ir/article-1-9871-en.html
URL: http://tumj.tums.ac.ir/article-1-9871-en.html
Ali Salehi1 
, Mohammad-Ali Abtahi1 , Seyed-Hossein Abtahi1 , Hasan Razmjou * 2, Mohammad Tohidi1 , Mojtaba Akbari3 , Hamidreza Jahanbani-Ardakani4
, Mohammad-Ali Abtahi1 , Seyed-Hossein Abtahi1 , Hasan Razmjou * 2, Mohammad Tohidi1 , Mojtaba Akbari3 , Hamidreza Jahanbani-Ardakani4
1- Eye Research Center, Feiz Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. Department of Ophthalmology, Feiz Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
2- Eye Research Center, Feiz Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. Department of Ophthalmology, Feiz Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. , hasan_razmju@yahoo.com
3- Department of Epidemiology, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
4- Isfahan Medical Students Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
2- Eye Research Center, Feiz Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. Department of Ophthalmology, Feiz Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. , hasan_razmju@yahoo.com
3- Department of Epidemiology, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
4- Isfahan Medical Students Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Abstract: (2485 Views)
Background: Retinal vein occlusions are one of the most common form of retinal vascular disorders and could lead to vision loss due to macular edema, macular ischemia and sequelae from neovascularization. Anti-venous endothelial growth factor (anti-VEGF) treatment is the choice strategy of treatment for patients with macular edema secondary to central retinal vein occlusion (CRVO). There is an evidence of body with the controversies regarding increment of choroidal thickness in CRVO condition. The current study was designed to determine whether baseline subfoveal choroidal thickness may be an indicator for visual and anatomical outcome of bevacizumab in patients with CRVO macular edema.
Methods: This study was a prospective clinical cohort study that enrolled in 23 new cases of treatment-naïve central retinal vein occlusion (CRVO) from February to July 2017 who were visited in Feiz Eye Hospital, Isfahan, Iran. Patients received a single injection of bevacizumab and were followed for 30 days. Ratio of subfoveal choroidal thickness (SFCT) was measured using enhanced depth imaging spectral-domain optical coherence tomography (EDI-OCT). Ratio of SFCT of the CRVO eye to the fellow healthy eye (SFCT1/F) was taken as independent variable. Changes of best-corrected visual acuity (BCVA) in LogMAR (ΔBCVA, functional response) and secondary to baseline central macular thickness ratio (CMT2/1, anatomical response) in the CRVO eyes were taken for comparative and correlative analytics.
Results: A total of 46 eyes from 23 patients with the mean age of 64.60±10.19 years were included in this study. Baseline SFCT was higher in CRVO eyes (251.91±46.09 µm) in comparison to the fellow eye (206.95±26.62, P<0.0001). Also central macular thickness in CRVO eyes were significantly higher in CRVO eyes in comparison with fellow eye (531.04±38.22 vs 303.30±33.59, respectively, P<0.05). SFCT1/F, correlated moderately with anatomical (CMT2/1) and strongly with functional response (ΔBCVA).
Conclusion: Bilateral evaluation of SFCT by EDI-OCT in all newly diagnosed CRVO cases is recommended to determine if there is a relative increase in choroidal thickness. This may help predict short-term response to anti-VEGF therapy.
Methods: This study was a prospective clinical cohort study that enrolled in 23 new cases of treatment-naïve central retinal vein occlusion (CRVO) from February to July 2017 who were visited in Feiz Eye Hospital, Isfahan, Iran. Patients received a single injection of bevacizumab and were followed for 30 days. Ratio of subfoveal choroidal thickness (SFCT) was measured using enhanced depth imaging spectral-domain optical coherence tomography (EDI-OCT). Ratio of SFCT of the CRVO eye to the fellow healthy eye (SFCT1/F) was taken as independent variable. Changes of best-corrected visual acuity (BCVA) in LogMAR (ΔBCVA, functional response) and secondary to baseline central macular thickness ratio (CMT2/1, anatomical response) in the CRVO eyes were taken for comparative and correlative analytics.
Results: A total of 46 eyes from 23 patients with the mean age of 64.60±10.19 years were included in this study. Baseline SFCT was higher in CRVO eyes (251.91±46.09 µm) in comparison to the fellow eye (206.95±26.62, P<0.0001). Also central macular thickness in CRVO eyes were significantly higher in CRVO eyes in comparison with fellow eye (531.04±38.22 vs 303.30±33.59, respectively, P<0.05). SFCT1/F, correlated moderately with anatomical (CMT2/1) and strongly with functional response (ΔBCVA).
Conclusion: Bilateral evaluation of SFCT by EDI-OCT in all newly diagnosed CRVO cases is recommended to determine if there is a relative increase in choroidal thickness. This may help predict short-term response to anti-VEGF therapy.
Keywords: bevacizumab, choroid, cohort studies, endothelial growth factors, intravitreal injections, optical coherence tomography, retinal vein occlusion, visual acuity
Type of Study: Original Article |
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
